Branimir I. Sikic, M. D.
Publications
- A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs. 2012; (3): 1082-7
- Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials. 2012; (2): 141-54
- Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest New Drugs. 2012; (6): 2364-70
- NFKBIA deletion in glioblastomas. N Engl J Med. 2011; (7): 627-37
- Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Invest New Drugs. 2011; (5): 971-7
- Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010; (11): 2970-81
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2010; (2): 376-81
- Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010; (5): 694-702
- A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res. 2008; (21): 7074-9
- Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol. 2008; (9): 1511-8
- Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007; (11): 1341-9
- Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Methods Mol Biol. 2007: 187-202
- A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. 2006; (7): 677-81
- Multidrug resistance and stem cells in acute myeloid leukemia. Clin Cancer Res. 2006; (11 Pt 1): 3231-2
- Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs. 2006; (2): 117-23
- Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer. 2006; (4): 365-74
- Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006; (2): 274-87
- A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs. 2005; (5): 467-77
- A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann Oncol. 2005; (12): 1968-73
- Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clin Lung Cancer. 2005: S6-12
- Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. J Mol Diagn. 2005; (2): 171-82
- Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005; (19): 8679-89
- Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci U S A. 2005; (49): 17763-8
- Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res. 2005; (20): 9388-97
- High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res. 2005; (10): 4088-96
- Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol. 2005; (24): 5613-9
- A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer. 2004; (2): 321-6
- A method for detecting and correcting feature misidentification on expression microarrays. BMC Genomics. 2004: 64
- CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol. 2004; (4): 906-16
- Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 2004; (9): 2646-54
- Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Lancet Oncol. 2004; (2): 89-100
- Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004; (6): 1078-86
- Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull Cancer. 2004; (5): E81-112
- Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. J Exp Ther Oncol. 2003 May-Jun; (3): 127-35
- Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003; (11): 4376-86
- Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003; (14): 5187-94
- Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Breast Cancer Res Treat. 2003; (1): 61-9
- Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther. 2002; (3): 215-25
- Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 2002; (5): 920-7
- Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer. 2002; (4): 372-83
- Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; (2): 259-69
- Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst. 2002; (10): 776-7; author reply 777
- A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res. 2001; (5): 1221-9
- Dominant effector genetics in mammalian cells. Nat Genet. 2001; (1): 23-9
- Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res. 2001; (10): 3215-21
- Clinical studies of antisense therapy in cancer. Front Biosci. 2000: D588-93
- Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin. Anticancer Drugs. 2000; (4): 303-9
- Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol. 2000; (4): 305-11
- Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). Mol Pharmacol. 2000; (4): 769-77
- MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Br J Cancer. 2000; (7): 892-8
- Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol. 2000; (9): 1867-75
- Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999; (3): 1061-70
- Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 1999; (2): 358-67
- Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park). 1999; (5A): 183-7
- New approaches in cancer treatment. Ann Oncol. 1999: 149-53
- Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res. 1999; (11): 3357-63
- Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol. 1999: 47-56
- Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999; (3): 787-95
- Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemother Pharmacol. 1998; (6): 517-21
- Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; (3): 203-9
- Validation of a limited sampling model to determine etoposide area under the curve. Pharmacotherapy. 1997 Sep-Oct; (5): 887-90
- Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997: S13-9
- Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997; (9): 5974-82
- Pharmacologic approaches to reversing multidrug resistance. Semin Hematol. 1997; (4 Suppl 5): 40-7
- Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. Br J Cancer. 1997; (2): 268-74
- Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997; (6): 601-3
- Differential expression of tubulin isotypes during the cell cycle. Cell Motil Cytoskeleton. 1996; (1): 49-58
- Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemother Pharmacol. 1996; (3): 210-6
- Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. Am J Physiol. 1996; (4 Pt 1): C1029-36
- Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic response predictions. Cancer Chemother Pharmacol. 1996; (3): 286-8
- Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer. 1996; (6): 1082-8
- Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 1996; (5): 1091-7
- Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am. 1995; (2): 363-82
- Cyclosporine A increases serum cortisol levels in rabbits. Anticancer Drugs. 1995; (4): 615-8
- Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst. 1995; (21): 1593-602
- Drug resistance in clinical oncology and hematology. Introduction. Hematol Oncol Clin North Am. 1995; (2): xi-xii
- Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol Pharmacol. 1995; (1): 51-6
- Glutathione-S-transferases pi, alpha, mu and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia. 1995; (10): 1742-7
- Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim Biophys Acta. 1995; (1): 1-8
- Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995; (10-11): 517-27
- The reversal of multidrug resistance. Cancer Treat Res. 1995: 45-70
- Analysis of intracellular retention of morpholinyl anthracyclines in multidrug-resistant cancer-cells by interactive laser cytometry. Int J Oncol. 1994; (6): 1273-7
- Clinical reversal of multidrug resistance. Cancer Treat Res. 1994: 149-65
- Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood. 1994; (2): 482-9
- Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia. 1994; (2): 327-35
- Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer. 1994; (1): 79-84
- Multidrug resistance in lymphomas. J Clin Oncol. 1994; (11): 2453-9
- Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst. 1994; (15): 1152-8
- Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994; (4): 835-42
- Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res. 1994; (18): 4980-7
- Volume-activated chloride current is not related to P-glycoprotein overexpression. Cancer Res. 1994; (19): 5029-32
- Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy. 1993 Mar-Apr; (2): 88-109
- Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993; (11 Suppl): 3502-14
- Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol. 1993; (1): 10-6
- Modulation of multidrug resistance: at the threshold. J Clin Oncol. 1993; (9): 1629-35
- Reversal of multidrug resistance to cancer chemotherapy. Cancer. 1993; (11 Suppl): 3484-8
- Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992; (10): 1635-42
- Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. J Natl Cancer Inst. 1992; (20): 1587-92
- Combined chemotherapy and radiotherapy for advanced-stage carcinomas of the cervix. Front Radiat Ther Oncol. 1992: 153-61
- Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol. 1992; (2): 145-52
- Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1992; (10): 1624-34
- Purging multidrug resistant cells from bone marrow. Prog Clin Biol Res. 1992: 13-23
- Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res. 1992; (16): 4379-84
- Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Int J Radiat Oncol Biol Phys. 1992; (4): 821-4
- Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol. 1992; (9): 1048-54
- Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. Prog Clin Biol Res. 1992: 25-34
- A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. Blood. 1991; (9): 2079-84
- Anticancer drug discovery. J Natl Cancer Inst. 1991; (11): 738-40
- Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Cancer. 1991; (5): 948-58
- Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991; (3): 586-92
- Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 1991; (19): 5181-7
- The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer. 1991; (6): 1518-24
- Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture. Exp Hematol. 1990; (8): 940-4
- Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. Gynecol Oncol. 1990; (2): 292-5
- Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol. 1990; (9): 1585-90
- Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. Exp Hematol. 1990; (11): 1193-8
- Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. Cancer Res. 1990; (13): 4056-60
- Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: a phase I-II prospective intergroup NCOG-RTOG Study. Gynecol Oncol. 1990; (1): 1-5
- Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer. 1990; (10): 2092-4
- Antitumor antibiotics. Curr Opin Oncol. 1989; (2): 198-202
- Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. J Natl Cancer Inst. 1989; (13): 1034-8
- Detection of cell-affecting agents with a silicon biosensor. Science. 1989; (4927): 243-7
- Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res. 1989; (24 Pt 1): 6901-5
- Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J Clin Oncol. 1988; (9): 1433-9
- Characterization and immunoassay of human tumor-associated galactosyltransferase isoenzyme II. Cancer Res. 1988; (18): 5325-34
- DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells. J Natl Cancer Inst. 1988; (16): 1294-8
- Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells. J Natl Cancer Inst. 1988; (5): 361-5
- Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. Cancer Res. 1988; (12): 3528-32
- A therapy planning architecture that combines decision theory and artificial intelligence techniques. Comput Biomed Res. 1987; (3): 279-303
- Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. Cancer Res. 1987; (22): 5954-9
- Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin. Cancer Chemother Pharmacol. 1987; (4): 282-6
- Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecol Oncol. 1986; (1): 68-80
- Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 1986; (1): 81-91
- High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group. Semin Oncol. 1986; (4 Suppl 4): 26-32
- In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma. Cancer Res. 1986; (4 Pt 1): 1748-53
- Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. Int J Radiat Oncol Biol Phys. 1986; (3): 385-9
- Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol. 1986; (3): 235-8
- Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res. 1986; (5): 2369-73
- Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group. Cancer Treat Rep. 1985 Jul-Aug; (7-8): 903-5
- Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. Cancer Res. 1985; (8): 3810-5
- Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat Rep. 1985; (5): 465-7
- Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science. 1985; (4707): 1544-6
- Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J Clin Invest. 1985; (1): 306-9
- Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985; (9): 4091-6
- Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol. 1984; (11): 1192-9
- Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. J Clin Oncol. 1984; (5): 385-90
- Second-look laparotomy in epithelial ovarian carcinoma: precise definition, sensitivity, and specificity of the operative procedure. Gynecol Oncol. 1984; (2): 154-60
- Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol. 1983; (10): 645-51
- Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med. 1983; (6): 823-33
- Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res. 1983; (10): 4943-50
- Diagnostic accuracies of clinical studies in patients with small cell carcinoma of the lung. J Clin Oncol. 1983; (5): 290-4
- Pulmonary toxicity of antitumor agents. Cancer Treat Rev. 1983; (4): 221-43
- Adsorption of antineoplastic drugs following large-volume ip administration to rats. Cancer Treat Rep. 1982; (1): 147-55
- Patterns of failure in small cell carcinoma of the lung. Cancer. 1982; (9): 1857-63
- Pulmonary disease as a complication of chlorozotocin chemotherapy. Cancer Treat Rep. 1981 Mar-Apr; (3-4): 223-9
- Human tumor clonogenic assays. An overview. Cancer Chemother Pharmacol. 1981; (3): 201-3
- Methodologic problems in clonogenic assays of spontaneous human tumors. Cancer Chemother Pharmacol. 1981; (3): 205-10
- Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A. Cancer Treat Rep. 1980 Apr-May; (4-5): 659-67
- Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats. Pharmacology. 1980; (6): 383-90
- Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980; (5): 1532-7
- Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol. 1980; (1): 21-6
- Enhancement of bleomycin activity against Lewis lung tumors in mice by local hyperthermia. Cancer Res. 1979; (9): 3792-5
- Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism. Biochem Pharmacol. 1979; (5): 683-5
- The distribution of 14C-imipramine in mice bearing Lewis lung carcinoma. Life Sci. 1979; (21): 1813-20
- The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol Appl Pharmacol. 1979; (1): 119-26
- Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits. Cancer Res. 1978; (5): 1420-5
- Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep. 1978; (12): 2011-7
- In vitro drug metabolism in male and female athymic, nude mice. Life Sci. 1978; (19): 1723-30
- Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology. Cancer Res. 1978; (3): 787-92
- Effects of dietary ascorbic acid supplementation on hepatic drug-metabolizing enzymes in the guinea pig. Biochem Pharmacol. 1977; (21): 2037-41
- The effects of ascorbic acid deficiency and repletion on pulmonary, renal, and hepatic drug metabolism in the guinea pig. Arch Biochem Biophys. 1977; (2): 663-71
- The interaction of flurazepam with diphenylhydantoin in the rat. Drug Metab Dispos. 1976 Nov-Dec; (6): 584-6
- Repeat administration of marihuana smoke to humans. Arch Gen Psychiatry. 1974; (1): 95-102
- An evaluation of a program for the treatment of alcoholism in Croatia. Int J Soc Psychiatry. 1972; (3): 171-82
Help
Trial Administration